Skip to main content

Market Overview

Looking Into Strongbridge Biopharma's Return On Capital Employed


During Q1, Strongbridge Biopharma (NASDAQ:SBBP) brought in sales totaling $8.38 million. However, earnings decreased 3.15%, resulting in a loss of $10.07 million. In Q4, Strongbridge Biopharma brought in $8.23 million in sales but lost $10.40 million in earnings.

What Is ROCE?

Changes in earnings and sales indicate shifts in Strongbridge Biopharma's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Strongbridge Biopharma posted an ROCE of -0.16%.

It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

For Strongbridge Biopharma, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.

Q1 Earnings Insight

Strongbridge Biopharma reported Q1 earnings per share at $-0.11/share, which did not meet analyst predictions of $-0.1/share.


Related Articles (SBBP)

View Comments and Join the Discussion!

Posted-In: BZI-ROCENews

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at